The ART-strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE

Journal of Hepatology

Volumn 60, Issue 1, 2014, Pages 118-126

  Hucke, Florian ^a   Sieghart, Wolfgang ^a   Pinter, Matthias ^a   Graziadei, Ivo ^b   Vogel, Wolfgang ^b   Müller, Christian ^a   Heinzl, Harald ^a   Waneck, Fredrik ^a   Trauner, Michael ^a   Peck Radosavljevic, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

ART score; HCC; Hepatocellular carcinoma; Prognosis; TACE

Indexed keywords

ALPHA FETOPROTEIN; C REACTIVE PROTEIN; DOXORUBICIN; IODINATED POPPYSEED OIL;

ADULT; AGED; ART SCORE; ARTICLE; ARTIFICIAL EMBOLISM; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; FEASIBILITY STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETREATMENT; SCORING SYSTEM; SEQUENTIAL ANALYSIS; ASSESSMENT FOR RE TREATMENT WITH TRANSARTERIAL CHEMOEMBOLIZATION; CANCER CLASSIFICATION; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; LIVER FUNCTION; PROGNOSTIC ASSESSMENT; STRATIFICATION; TREATMENT DURATION;

ART SCORE; HCC; HEPATOCELLULAR CARCINOMA; PROGNOSIS; TACE;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 84890567147     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.08.022     Document Type: Article

References (17)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
2. J.M. Llovet, C. Bru, and J. Bruix Prognosis of hepatocellular carcinoma: the BCLC staging classification Semin Liver Dis 19 1999 329 338
3. A. Forner, M.E. Reig, C.R. de Lope, and J. Bruix Current strategy for staging and treatment: the BCLC update and future prospects Semin Liver Dis 30 2010 61 74
4. J. Bruix, M. Sherman, J.M. Llovet, M. Beaugrand, R. Lencioni, and A.K. Burroughs Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430
5. EASL-EORTC clinical practice guidelines Management of hepatocellular carcinoma J Hepatol 56 2012 908 943
6. F. Hucke, W. Sieghart, M. Schoniger-Hekele, M. Peck-Radosavljevic, and C. Muller Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program? Wien Klin Wochenschr 123 2011 542 551
7. J.M. Llovet, and J. Bruix Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 2003 429 442
8. J.L. Raoul, B. Sangro, A. Forner, V. Mazzaferro, F. Piscaglia, and L. Bolondi Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization Cancer Treat Rev 37 2011 212 220
9. L. Bolondi, A. Burroughs, J.F. Dufour, P.R. Galle, V. Mazzaferro, and F. Piscaglia Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions Semin Liver Dis 32 2012 348 359
10. W. Sieghart, F. Hucke, M. Pinter, I. Graziadei, W. Vogel, and C. Mueller The ART of decision making: re-treatment with TACE in patients with hepatocellular carcinoma Hepatology 2013 10.1002/hep.26256
11. E. Terzi, R. Golfieri, F. Piscaglia, M. Galassi, A. Dazzi, and S. Leoni Response rate and clinical outcome of HCC after first and repeated cTACE performed "on demand" J Hepatol 57 2012 1258 1267
12. M. Peck-Radosavljevic, W. Sieghart, C. Kolblinger, M. Reiter, M. Schindl, and G. Ulbrich Austrian Joint OGGH-OGIR-OGHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma Wien Klin Wochenschr 124 2012 104 110
13. L Sobin, and C Wittekind TNM classification of malignant tumours 6th ed. 2002 UICC New York
14. W. Sieghart, M. Pinter, F. Hucke, I. Graziadei, M. Schoniger-Hekele, and C. Muller A single determination of C-reactive protein at the time of diagnosis predicts long term outcome of patients with hepatocellular carcinoma Hepatology 2012 10.1002/hep.26057
15. C.G. Child, and J.G. Turcotte Surgery and portal hypertension Major Probl Clin Surg 1 1964 1 85
16. K. Memon, L. Kulik, R.J. Lewandowski, E. Wang, R.K. Ryu, and A. Riaz Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis J Hepatol 56 2012 1112 1120
17. A. Trotti, A.D. Colevas, A. Setser, V. Rusch, D. Jaques, and V. Budach CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 2003 176 181